Most people who pursue IVF will need more than one cycle, and the clearest data suggest that cumulative success climbs steadily through about six cycles before leveling off. A large UK study tracking over 156,000 women found that roughly two out of three achieved a live birth by the sixth cycle, with per-cycle live-birth rates holding above 20% through the fourth attempt. The “right” number of cycles varies enormously depending on age, ovarian reserve, the cause of infertility, and how a clinic defines a cycle, but for many patients the realistic planning horizon is two to four stimulation cycles, with frozen embryo transfers extending the usable embryos from each one.
Cumulative Live-Birth Rates Across Multiple Cycles
The single most useful number for IVF planning is the cumulative live-birth rate, which tells you the running total chance of taking home a baby as you add more cycles. A study published in the New England Journal of Medicine followed over 6,000 women through more than 14,000 cycles and found cumulative live-birth rates of 51% to 72% after six cycles, depending on how they counted women who dropped out. The lower number assumed every dropout failed; the higher number excluded them from the denominator. Reality sits somewhere between the two.
A more recent and much larger analysis from the UK’s Human Fertilisation and Embryology Authority, covering over 156,000 women, reported a cumulative prognosis-adjusted live-birth rate of about 65% after six cycles. The per-cycle live-birth rate in the first attempt was close to 30%, and it stayed above 20% through the fourth cycle. Gains continued through the ninth cycle, although each additional attempt added less than the one before.
A single-center study reported a conservative cumulative rate of about 57% after three cycles, climbing to roughly 68% after six. These numbers are broadly consistent across different datasets and reinforce the same pattern: the first few cycles contribute the most, but meaningful gains continue well beyond the third attempt.
Age Is the Strongest Predictor
No other variable shifts cycle-to-cycle odds as powerfully as the age of the person providing the eggs. In the New England Journal of Medicine study, women under 35 had cumulative rates between 65% and 86% after six cycles, while women 40 and older reached only 23% to 42% over the same number of attempts. A separate review of over 2,700 cycles in women aged 40 and above found cumulative live-birth rates starting at about 28% for those beginning at age 40 and falling to zero by age 46.
The practical upshot is that younger patients can often afford to try additional cycles because each attempt still carries a reasonable chance. For patients over 40 using their own eggs, the per-cycle rate drops more steeply after the first two or three tries, and at some point the odds of success in any single additional cycle become very small. This is why many clinics discuss the option of donor eggs earlier in the process for older patients. In donor-egg cycles, cumulative live-birth rates in one study reached about 66% to 70% after using all embryos from the donation.
What Counts as a “Cycle” Matters
When clinics and studies quote cycle counts, they sometimes mean different things. A stimulation cycle, often called a “complete cycle,” includes the egg retrieval plus any fresh and frozen embryo transfers that result from it. A transfer cycle counts each individual embryo transfer separately. Two frozen transfers from a single egg retrieval are one complete cycle but two transfer cycles. This distinction matters because a single stimulation can generate multiple usable embryos and therefore multiple transfer opportunities without repeating the hormone injections and retrieval procedure.
When a study reports that success reaches a certain threshold by cycle three, you need to know whether they mean three stimulations or three transfers. A predictive model validated across multiple clinics estimated that a 30-year-old woman with primary infertility had about a 41% chance of a live birth in her first complete cycle and 75% over three complete cycles. A separate model estimated that a 34-year-old woman with a normal ovarian reserve had roughly a 62% chance in her first complete cycle and about 89% across three. The difference between these estimates likely reflects differences in patient populations and the number of embryos produced per retrieval, but both underscore that a “complete cycle” carries more cumulative power than a single transfer.
Blastocyst Versus Cleavage-Stage Transfers
One decision that influences how many transfers you need within each stimulation cycle is when the embryo is transferred. A Cochrane review found that transferring embryos at the blastocyst stage, five days after fertilization, improved live-birth rates per fresh transfer compared with transferring at the cleavage stage on day two or three. The review estimated that if about 31% of women achieved a live birth after a cleavage-stage transfer, somewhere between 32% and 41% would do so after a blastocyst transfer.
A large multicenter randomized trial from China confirmed this, reporting cumulative live-birth rates of about 75% for single blastocyst transfer versus 66% for single cleavage-stage transfer among women with a good prognosis. However, a European trial published in the BMJ found no meaningful difference in cumulative live-birth rates between the two strategies, with both groups landing near 59%. The discrepancy likely comes down to differences in lab culture conditions and patient selection. In practice, most large clinics now default to blastocyst transfer when enough embryos are developing well, but the advantage is not universal.
Fresh Versus Frozen Transfers
Whether to transfer an embryo fresh during the same cycle as retrieval or freeze everything and transfer later has become a surprisingly contentious question. A retrospective study of over 7,200 cycles found that freezing all embryos and transferring later was associated with higher cumulative live-birth rates in women who produced a normal or high number of eggs, but there was no benefit for those with a poor response. In women who responded well, cumulative rates ran about 4 to 5 percentage points higher with a freeze-all approach.
A randomized trial comparing the two strategies in a general population found that the conventional approach, transferring one embryo fresh and freezing the rest, actually led to more ongoing pregnancies than freezing everything. The cumulative live-birth rates between the two arms were not significantly different. The takeaway for cycle planning is that a freeze-all strategy does not universally improve your odds. It can help certain patients, especially those at risk of ovarian hyperstimulation, but for others a fresh transfer on the first attempt is at least as effective.
When Success Rates Seem to Stall
Some patients experience repeated implantation failure, where multiple embryo transfers do not result in pregnancy. A natural question is whether the per-transfer success rate eventually drops to zero, suggesting that something fundamentally prevents implantation. A large study examined nearly 124,000 patients who transferred genetically tested normal embryos and found that even after four consecutive failed transfers of chromosomally normal blastocysts, the live-birth rate on the fifth transfer was about 53%. The cumulative live-birth rate after five such transfers reached 98%.
This is a striking finding because it implies that for patients using genetically screened embryos, true “implantation failure” as a fixed biological barrier is extremely rare. Each transfer still carries roughly the same odds as the one before. The practical limitation is that most patients do not have five normal embryos available, especially at older ages, so the bottleneck is usually the egg retrieval and embryo production side rather than the uterus refusing to cooperate.
Factors That Can Reduce Success Per Cycle
Beyond age, several conditions affect how many cycles you may need. Body weight is one of the more consistent predictors. A national cohort study found that cumulative live-birth rates fell from about 33% in normal-weight women to 27% in women with class I obesity and dropped sharply to under 8% in women with class III obesity. A longitudinal study following nearly 500 women over five years confirmed that higher BMI independently predicted lower live-birth rates per cycle, alongside the woman’s age and her partner’s age.
Uterine conditions also play a role. Women with endometriosis or adenomyosis diagnosed on ultrasound had about a 15% lower chance of achieving a cumulative live birth over three consecutive IVF treatments compared to women without these conditions. Adenomyosis in particular was associated with higher miscarriage rates and lower live-birth rates even when patients received hormone pretreatment before frozen embryo transfers, with worse outcomes in women 38 and older.
Sperm quality matters too, though the picture is more nuanced. Two meta-analyses found that high sperm DNA damage is associated with lower implantation and pregnancy rates in conventional IVF, but the effect largely disappears when the sperm is injected directly into the egg using ICSI. A separate study found that when the same number of eggs were available, cumulative live-birth rates were similar regardless of the degree of sperm DNA damage, suggesting that ICSI effectively compensates for this problem in most cases.
Switching Protocols After a Failed Cycle
If a first cycle fails or is cancelled, one reasonable question is whether changing the stimulation protocol helps. An analysis of over 13,000 cycles reported to a U.S. registry found that switching protocols after a cancelled cycle was associated with about a 14% lower chance of another cancellation and a 17% higher chance of a live birth from a fresh transfer. Among patients whose first cycle was cancelled due to a poor response, the improvement was even more pronounced, with about a 20% lower risk of repeat cancellation.
For patients who have had multiple failed embryo transfers, a systematic review examined several experimental interventions. Infusion of certain immune cells into the uterus before transfer roughly doubled clinical pregnancy and live-birth rates in pooled analyses, though the studies were small and the evidence remains preliminary. These are not standard treatments and are generally offered only after several failures, but they represent options that some clinics explore when conventional approaches have not worked.
Genetic Screening and Its Effect on Cycle Count
Preimplantation genetic testing for aneuploidy, commonly called PGT-A, screens embryos for chromosome abnormalities before transfer. The idea is that transferring only genetically normal embryos should reduce miscarriages and wasted transfers, potentially shortening the path to a live birth. The reality is mixed. A large analysis of over 133,000 first stimulation cycles found that PGT-A was associated with lower cumulative live-birth rates in women 40 and younger.
A multicenter retrospective study found that PGT-A did not significantly improve time to live birth for patients under 39. However, in patients 39 and older, PGT-A was associated with a significantly shorter time to live birth. This makes biological sense: older patients produce a higher proportion of chromosomally abnormal embryos, so the screening filters out more non-viable transfers. For younger patients who produce mostly normal embryos, the testing adds cost and may discard embryos that would have been fine.
Why People Stop Before Reaching Cumulative Success
The gap between the theoretical cumulative success rate after six cycles and what patients actually achieve is largely explained by dropout. Many couples stop treatment before exhausting their realistic chances. The reasons are layered. In one survey, financial burden was the primary reason for discontinuation. A U.S. study of insured patients, who had the financial barrier partially removed, found that stress was the most common reason for stopping, cited by about 39% of respondents. The main sources of stress were the toll on the couple’s relationship and overwhelming anxiety or depression.
A qualitative study explored how couples make the decision to keep going or stop. Many described continuing with IVF not because they expected it to work but because they feared regretting the decision to stop. One participant described pursuing additional cycles “purely to avoid an emotional or psychological issue later in my life when I look back and think I didn’t do enough,” despite believing the cycles would not succeed. This pattern of regret avoidance complicates the question of how many cycles to attempt because the decision is rarely driven by statistics alone.
Insurance Coverage Changes the Math
Access to insurance-covered IVF directly affects how many cycles patients attempt and how those cycles turn out. A study comparing U.S. states with comprehensive IVF insurance mandates to those without found that utilization was 132% higher in mandated states. Live-birth rates per cycle were also higher in states with comprehensive coverage, about 35% compared to 33% in states without. Multiple-birth rates were lower in mandated states, likely because patients and clinics felt less pressure to transfer multiple embryos when insurance would cover another attempt.
The implication is that when financial barriers are lowered, patients attempt more cycles, clinics transfer fewer embryos per cycle, and outcomes improve across the board. For patients paying out of pocket, the cost of each cycle compresses the number of attempts into a smaller window, which can lead to more aggressive embryo transfer practices and paradoxically worse outcomes through higher rates of risky multiple pregnancies.
Personalized Prediction Models
Rather than relying on population averages, some clinics now use prediction models that estimate your individual cumulative chance based on specific characteristics. The most validated models use age, duration and cause of infertility, and sometimes ovarian reserve markers. After a first cycle, the model can incorporate how many eggs were retrieved and embryos produced to sharpen the estimate.
An external validation study found that a pre-treatment model had moderate accuracy, with predictions that needed to be adjusted downward because the original model was somewhat optimistic. The post-treatment model, which incorporates actual first-cycle results, performed better. As an example from the updated model, a 30-year-old woman with two years of primary infertility had an estimated 41% chance in her first complete ICSI cycle and 75% over three. Adding ovarian reserve markers like AMH and antral follicle count slightly improved the pre-treatment model’s accuracy but did not meaningfully help the post-treatment model, since the first cycle’s results already captured much of the same information.
AMH, the hormone often used to gauge ovarian reserve, becomes a more useful predictor with age. A retrospective study found that AMH had essentially no predictive value for women under 30 but became increasingly correlated with outcomes in older age groups, with the strongest association in women over 40. For younger patients, a low AMH might prompt concern about how many eggs a cycle will produce, but it does not reliably predict whether those eggs will result in a baby.
How Long Per-Cycle Rates Stay Meaningful
One persistent myth is that IVF “stops working” after three failed cycles. The data do not support a hard cutoff. The large UK registry study showed per-cycle live-birth rates remaining above 20% through the fourth attempt and continuing to add meaningfully to cumulative totals through the ninth cycle. An older but often-cited study found that pregnancy and delivery rates declined after the fourth cycle, dropping from about 27% delivery rate in cycles one through three to about 16% in cycle four and 15% beyond that. That is a real decline, but 15% per attempt is still a meaningful chance for each individual patient.
The challenge is distinguishing between the natural selection effect, where patients who succeed leave the pool, making the remaining group look less successful, and a genuine biological decline in per-cycle odds for the same person. Some of the apparent drop in per-cycle rates simply reflects the fact that the easiest-to-treat patients have already conceived, leaving a group enriched for harder cases. This is why prognosis-adjusted rates, which attempt to account for this selection, tend to show flatter per-cycle rates than raw data.
For the individual patient weighing whether to try again, the question is not what the average success rate is for “cycle five patients” but what their own specific characteristics predict. A 33-year-old with unexplained infertility who had a good embryo response but bad luck with implantation has a fundamentally different outlook than a 42-year-old with diminished ovarian reserve who has produced only one or two embryos per retrieval. Population averages are a starting point, not a verdict.